CD274 and cancer: Moreover, variations in PD-L1 expression thresholds, the incidence range of MSI-H/dMMR in cancers (1% to 25%) (10), the dependence of TMB tests reliability on tissue specimens quality, and the limited accessibility of biopsy specimens for aNSCLC patients underscore the urgency in identifying novel, tailored prognostic markers to predict the efficacy of ICIs therapy.